Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
IPO Year: 2011
Exchange: NASDAQ
Website: horizontherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $74.00 | Neutral | H.C. Wainwright |
| 8/4/2022 | Outperform → Mkt Perform | SVB Leerink | |
| 6/14/2022 | $139.00 | Buy | UBS |
| 6/6/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 5/23/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 3/15/2022 | $140.00 | Outperform | Oppenheimer |
| 3/2/2022 | $135.00 → $140.00 | Overweight | Morgan Stanley |
| 12/8/2021 | $137.00 | Overweight | Wells Fargo |
| 11/19/2021 | $168.00 | Neutral → Buy | Goldman Sachs |
| 10/7/2021 | $132.00 | Buy | Jefferies |
15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the Scheme becoming effective Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that the Irish H
Horizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Gino Santini (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securit
IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: James Shannon, M.D. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Us
-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the U.S. Food and Drug Administration, the European Commission and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). Presentation Details: P015: Association of Cytokine P
IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Michael Grey (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a sep
-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on the impact of TED on quality of life (QOL) -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by lengthening the amount of time between infusions can increase the need for a second course of treatment. These findings, along with new subgroup data from the TEPEZZA Phase 4 clinical trial in patients with long disease duration and low Clinical Activity Score (CAS) and an analysis of the impact of TED on QOL, were shared at the 92nd Annual Meeting of the American Thyroid Association (ATA 2
IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Jeff Himawan (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a sep
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to U.S. News & World Report's 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing. "We are honored to be named to the inaugural U.S. News & World Report Best Companies to Work For in the Health Care Industry list," said Tim Walbert, chairman, president and chief executive officer, Horizon. "Building and nurturing a culture of inclusiveness and offering world-class benefits to our employees has laid the foundation for Horizon to become the fast-growing biotech it is today." Guided by a panel of experts, editors from U.S. News & W
IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Gino Santini (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
Horizon Therapeutics's (NYSE:HZNP) short percent of float has fallen 25.18% since its last report. The company recently reported that it has 7.10 million shares sold short, which is 3.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.38 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short
-8-K As previously disclosed, on December 11, 2022, Horizon Therapeutics plc (“Horizon”), Amgen Inc. (“Amgen”) and Pillartree Limited, a whollyowned subsidiary of Amgen (“Acquirer Sub”), entered into a Transaction Agreement pursuant to which, among other things, Acquirer Sub willacquire the entire issued ordinary share capital of Horizon (the “Acquisition”) through a court-sanctioned scheme of arrangement underChapter 1 of Part 9 of the Irish Companies Act 2014 (the “Scheme”).On October 5, 2023, the High Court of Ireland (the “Court”) sanctioned the Scheme. Completion of the Acquisition remains subject to thedelivery to the Registrar of Companies in Ireland of a copy of the order of the Cou
Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 5 years by 36.06% on an annualized basis producing an average annual return of 44.12%. Currently, Horizon Therapeutics has a market capitalization of $26.62 billion. Buying $100 In HZNP: If an investor had bought $100 of HZNP stock 5 years ago, it would be worth $640.52 today based on a price of $116.23 for HZNP at the time of writing. Horizon Therapeutics's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga'
-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses --Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the U.S. Food and Drug Administration, the European Commission and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).Presentation Details:P015: Association of Cytokine Proteins wit
-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on the impact of TED on quality of life (QOL) --Horizon Therapeutics plc (NASDAQ:HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by lengthening the amount of time between infusions can increase the need for a second course of treatment. These findings, along with new subgroup data from the TEPEZZA Phase 4 clinical trial in patients with long disease duration and low Clinical Activity Score (CAS) and an analysis of the impact of TED on QOL, were shared at the 92nd Annual Meeting of the American Thyroid Association (ATA 2023)
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BCLI PUT TRADE BULLISH 10/20/23 $1.00 $200.0K 17.5K 11.8K CVS CALL TRADE BEARISH 11/1
Horizon Therapeutics's (NYSE:HZNP) short percent of float has risen 20.52% since its last report. The company recently reported that it has 9.48 million shares sold short, which is 4.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.13 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short i
Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart --
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings. Below are the ratings of the most accurate analysts for three high-yielding stocks in the h
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre
THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly see
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831157622/en/ As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern D
Second-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $445.5 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $244.3 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $68.1 Million -- -- Cash Position of $2.5 Billion as of June 30, 2023 -- Second-Quarter and Recent Company Highlights: -- Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) -- -- Obtained U.S. FDA Approva
Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be publicly available on the Investor Relations page of its website at https://ir.horizontherapeutics.com. About Horizon Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and sever
First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $405.3 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $187.0 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $53.8 Million -- -- Cash Position of $2.31 Billion as of March 31, 2023 -- First-Quarter and Recent Company Highlights: -- Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) -- -- Obtained U.S. FDA Approval for Updated TEPEZZA Indication to Specify Treatment of TED Patients Regard
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre
Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be publicly available on the Investor Relations page of its website at https://ir.horizontherapeutics.com. About Horizon Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and sever
Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $493.5 Million -- -- KRYSTEXXA® (pegloticase injection) Net Sales of $216.1 Million -- -- UPLIZNA® (inebilizumab-cdon) Net Sales of $41.8 Million -- Full-Year 2022 Results: -- Record Net Sales of $3.63 Billion; Year-Over-Year Increase of 12% -- -- GAAP Net Income of $521.5 Million; Record Adjusted EBITDA of $1.37 Billion; Includes $56.3 Million of Acquired IPR&D and Milestones Expenses -- -- Record TEPEZZA Net Sales of $1.97 Billion; Year-Over-Y
-- Record Third-Quarter 2021 Net Sales of $1.037 Billion Increased 63 Percent; Third-Quarter 2021 GAAP Net Income of $326.5 Million; Record Adjusted EBITDA of $509.0 Million -- -- Record TEPEZZA® (teprotumumab-trbw) Third-Quarter 2021 Net Sales of $616.4 Million; Increasing Full-Year 2021 Net Sales Guidance to Greater Than $1.625 Billion, Representing Year-Over-Year Growth of More Than 98 Percent -- -- Record KRYSTEXXA® (pegloticase injection) Third-Quarter 2021 Net Sales of $158.1 Million; KRYSTEXXA Plus Immunomodulation Now at More Than 45 Percent; Increasing Full-Year 2021 Net Sales Guidance to Greater Than $550 Million, Representing Year-Over-Year Growth of More Than 35 Percent -- --
H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00
SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform
UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00
SVB Leerink resumed coverage of Horizon Pharma with a rating of Mkt Perform and set a new price target of $95.00
SVB Leerink initiated coverage of Horizon Pharma with a rating of Mkt Perform and set a new price target of $95.00
Oppenheimer initiated coverage of Horizon Pharma with a rating of Outperform and set a new price target of $140.00
Morgan Stanley reiterated coverage of Horizon Therapeutics with a rating of Overweight and set a new price target of $140.00 from $135.00 previously
Wells Fargo initiated coverage of Horizon Pharma with a rating of Overweight and set a new price target of $137.00
Goldman Sachs upgraded Horizon Therapeutics from Neutral to Buy and set a new price target of $168.00
Jefferies resumed coverage of Horizon Pharma with a rating of Buy and set a new price target of $132.00